Biomarin Pharmaceutical - Registered Shares Overview
Biomarin Pharmaceutical - Registered Shares Target Price
Analysts' 12-month price predictions for BMRN.
Share Price
$77.56
Average Target Price
$97.25
25.4% upside
25.4% upside4 analysts in the last 4 months
High: $119 | Low: $72
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2024-05-17 | Robert W. BairdJack Allen | $72 |  7.2% downside |  |
| 2024-05-13 | Evercore ISICory Kasimov | $113 | 45.7% upside | |
| 2024-04-25 | ScotiabankGeorge Farmer | $85 | 9.6% upside | |
| 2024-04-22 | UBSEliana Merle | $119 | 53.4% upside | |
| 2023-07-05 | BMO CapitalKostas Biliouris | $102 | 31.5% upside | |
| 2022-10-26 | Raymond JamesChristopher Raymond | $128 | 65% upside | |
| 2022-09-12 | Truist FinancialRobyn Karnauskas | $133 | 71.5% upside | |
| 2022-07-12 | Cantor FitzgeraldOlivia Brayer | $110 | 41.8% upside | |
| 2022-04-25 | Morgan StanleyMatthew Harrison | $113 | 45.7% upside | |
| 2022-02-22 | Evercore ISIJoshua Schimmer | $105 | 35.4% upside | |
| 2022-02-18 | Morgan StanleyMatthew Harrison | $90 | 16% upside | |
| 2022-01-10 | Bank of America SecuritiesGeoff Meacham | $120 | 54.7% upside | |
| 2021-12-08 | Cowen & Co.Phil Nadeau | $135 | 74.1% upside | |
| 2021-11-22 | Credit SuisseTiago Fauth | $105 | 35.4% upside | |
| 2021-11-19 | GuggenheimDebjit Chattopadhyay | $120 | 54.7% upside | |